REVIEW OF THE 2017 AMERICAN COLLEGE OF RHEUMATOLOGY/AMERICAN ASSOCIATION OF HIP AND KNEE SURGEONS GUIDELINES FOR THE PERIOPERATIVE MANAGEMENT AND ANTIRHEUMATIC THERAPY OF PATIENTS WITH RHEUMATIC DISEASES BEFORE TOTAL KNEE AND HIP ARTHROPLASTY

The article presents the guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons for the perioperative management of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, or systemic lupus erythematosus who are undergoing elective total hip or knee arthroplasty. It considers the perioperative use of antirheumatic drug therapy, including disease-modifying anti-inflammatory drugs, biological agents, tofacitinib, and glucocorticoids. All recommendations are conditional and based on the results of retrospective clinical trials, which should be considered when making decisions about perioperative antirheumatic therapy.